Lehmann J., Hutchison A. J., McPherson S. E., Mondadori C., Schmutz M., Sinton C. M., et al. (July 1988). "CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist". The Journal of Pharmacology and Experimental Therapeutics. 246 (1): 65–75. PubMed:2899170
Bennett D. A., Lehmann J., Bernard P. S., Liebman J. M., Williams M., Wood P. L., et al. (1990). "CGS 19755: a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant, anxiolytic and anti-ischemic properties". Progress in Clinical and Biological Research. 361: 519–24. PubMed:1981269
France C. P., Winger G. D., Woods J. H. (September 1990). "Analgesic, anesthetic, and respiratory effects of the competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys". Brain Research. 526 (2): 355–8. doi:10.1016/0006-8993(90)91247-e. hdl:2027.42/28393. PubMed:2257491
Grotta J., Clark W., Coull B., Pettigrew L. C., Mackay B., Goldstein L. B., et al. (April 1995). "Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial". Stroke. 26 (4): 602–5. doi:10.1161/01.str.26.4.602. PubMed:7709405
Bennett D. A., Bernard P. S., Amrick C. L., Wilson D. E., Liebman J. M., Hutchison A. J. (August 1989). "Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors". The Journal of Pharmacology and Experimental Therapeutics. 250 (2): 454–60. PubMed:2547931
Koek W., Woods J. H., Colpaert F. C. (June 1990). "N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis". The Journal of Pharmacology and Experimental Therapeutics. 253 (3): 1017–25. PubMed:2193142
Lu Y., France C. P., Woods J. H. (November 1992). "Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists". The Journal of Pharmacology and Experimental Therapeutics. 263 (2): 499–504. PubMed:1432686
Baron S. P., Woods J. H. (March 1995). "Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine". Psychopharmacology. 118 (1): 42–51. doi:10.1007/bf02245248. hdl:2027.42/46346. PubMed:7597121
Morris G. F. et al. (November 1999). "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators". Journal of Neurosurgery. 91 (5): 737–43. doi:10.3171/jns.1999.91.5.0737. PubMed:10541229
Davis S. M. et al. (February 2000). "Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist". Stroke. 31 (2): 347–54. doi:10.1161/01.str.31.2.347. PubMed:10657404
Dawson D. A., Wadsworth G., Palmer A. M. (February 2001). "A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke". Brain Research. 892 (2): 344–50. doi:10.1016/s0006-8993(00)03269-8. PubMed:11172782
Ikonomidou C., Turski L. (October 2002). "Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?". The Lancet. Neurology. 1 (6): 383–6. doi:10.1016/s1474-4422(02)00164-3. PubMed:12849400
Farin A., Marshall L. F. (2004). "Lessons from epidemiologic studies in clinical trials of traumatic brain injury". Acta Neurochirurgica. Supplement. 89: 101–7. doi:10.1007/978-3-7091-0603-7_14. ISBN 978-3-7091-7206-3. PubMed:15335108
